<DOC>
	<DOCNO>NCT00068601</DOCNO>
	<brief_summary>RATIONALE : Goserelin block hormone production ovary . It yet know whether ovarian suppression use goserelin prevent ovarian failure ( early menopause ) woman receive chemotherapy breast cancer . PURPOSE : This randomized phase III trial study well give goserelin together chemotherapy work compare chemotherapy alone prevent early menopause woman stage I , stage II , stage IIIA breast cancer .</brief_summary>
	<brief_title>S0230 Goserelin Preventing Ovarian Failure Women Receiving Chemotherapy Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare rate premature ovarian failure woman stage I-IIIA hormone receptor-negative breast cancer treat chemotherapy v without goserelin . Secondary - Compare rate ovarian dysfunction patient treat regimen . - Compare ovarian reserve patient treat regimen . - Describe pregnancy rate patient treat regimen . OUTLINE : This randomize study . Patients stratify accord age ( 40 vs 40 49 ) plan chemotherapy regimen ( 3- 4-month/course anthracycline-based vs 6- 8-month/course anthracycline-based vs 3- 4-month/course non-anthracycline-based vs 6- 8-month/course non-anthracycline-based ) . Patients randomize 1 2 treatment arm . - Arm 1 : Patients receive cyclophosphamide-containing chemotherapy alone . Patients follow 1 , 2 , 5 year . - Arm 2 : Patients receive goserelin subcutaneously every 4 week begin 1 week start cyclophosphamide-containing chemotherapy . Treatment continue completion chemotherapy absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 416 patient ( 208 per treatment arm ) accrue study within 3 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive breast cancer Stage IIIIA Operable disease Bilateral synchronous invasive breast cancer allow provide primary tumor diagnose 1 month apart tumors hormone receptor negative Must plan receive 38 month preoperative postoperative chemotherapy regimen contain alkylating agent ( anthracyclines nonanthracyclines ) , meet 1 follow criterion : 3month/4course anthracyclinebased regimen 6 8month/course anthracyclinebased regimen 6 8month/course nonanthracyclinebased regimen Hormone receptor status : Estrogen receptor negative Progesterone receptor negative PATIENT CHARACTERISTICS : Age 18 49 Sex Female Menopausal status Premenopausal Performance status Zubrod 02 Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Other Not pregnant nursing Fertile patient must use effective barrier contraception No prior malignancy except adequately treat basal cell squamous cell skin cancer situ cancer patient diseasefree least 5 year treatment curative intent PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics No prior cytotoxic chemotherapy Endocrine therapy No concurrent hormonal therapy Radiotherapy Concurrent radiotherapy breast , chest wall , lymph node allow Surgery See Disease Characteristics Other Concurrent participation therapeutic clinical trial , include SWOGS0221 , allow</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>infertility</keyword>
	<keyword>menopausal symptom</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
	<keyword>estrogen receptor-negative breast cancer</keyword>
	<keyword>progesterone receptor-negative breast cancer</keyword>
</DOC>